Clinical trial
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML
NCT00303290 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00303290 |
|---|---|
| Title | PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML |
| Official title | Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With SCH54031 (PEG Interferon Alpha 2B/PEG Intron) and Low-Dose Cytosine Arabinoside (Ara-C) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Schering-Plough Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Peg Interferon Alpha 2b (Peg Intron), Ara-C (cytosine arabinoside) |
| Enrollment | 76 |
| Start date | Jan 1, 2000 |
| Primary completion | Nov 1, 2014 |
| Completion | Nov 1, 2014 |
| First posted | Mar 16, 2006 |
| Last update posted | Nov 26, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: